Carboplatin: Side Effects, Uses & Monitoring
Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents.
- Data source
- FDA labeling via NIH DailyMed (label f4baa639…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Leukopenia | 98% |
| Nausea and vomiting | 98% |
| Neutropenia | 97% |
| Vomiting | 97% |
| Anemia | 91% |
| Magnesium | 88% |
| <1,000 cells/mm | 81% |
| Thrombocytopenia | 70% |
| <2,000 cells/mm | 68% |
| Other gi side effects | 62% |
| Transfusions | 42% |
| Peripheral neuropathies | 42% |
| <50,000/mm | 41% |
| Central neurotoxicity | 40% |
| Asthenia | 40% |
| Pain | 37% |
| Ototoxicity | 33% |
| Blood urea elevations | 31% |
| Alkaline phosphatase elevations | 29% |
| Potassium | 22% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin, USP vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously trea…
Conditions associated with Carboplatin in labeling
Frequently Asked Questions
What is Carboplatin used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Carboplatin?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Carboplatin. Individual risk varies.
Does Carboplatin require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Carboplatin.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.